KPMG Healthcare & Pharmaceutical Institute

An Overview of Risk and Disclosure in the Global Pharmaceutical and Life Sciences Industry Healthcare & Pharmaceutical Institute | May 16, 2012 | Healthcare & Pharmaceutical This is a summary report of risk and disclosure by the major pharmaceutical and life sciences companies.

Future Pharma Healthcare & Pharmaceutical Institute | May 16, 2012 | Healthcare & Pharmaceutical Future Pharma presents four key challenges facing the Pharmaceutical Industry and five strategies to accelerate the transformation of the industry to meet those challenges.

KPMG Poll: 'Meaningful Use' Requirements Seen as Compliance Challenge, Despite High Hospital EHR Adoption Rates Healthcare & Pharmaceutical Institute | April 26, 2012 | A KPMG poll finds that "meaningful use" requirements are seen as a compliance challenge, despite high hospital electronic health record (EHR) adoption rates.

Accelerating Innovation: The Power of the Crowd Healthcare & Pharmaceutical Institute | March 22, 2012 | Healthcare & Pharmaceutical Accelerating Innovation - The Power of the Crowd is an essential read for healthcare leaders in pursuit of the transformational benefits of implementing sustainable eHealth programs.

A Key to Successful EHR Implementation - Quality Assurance and Independent Verification and Validation Healthcare & Pharmaceutical Institute | Feb. 15, 2012 | Healthcare & Pharmaceutical QA/IV&V brings an objective, independent review of a projectÂ’s plans and implementation strategies to provide a risk-based overview of the change management plans, training schedules, data collection and other critical elements to monitor whether an EHR implementation is going smoothly and delivering the provider's objectives.

The KPMG Healthcare Meaningful Use Readiness Assessment Healthcare & Pharmaceutical Institute | Feb. 15, 2012 | Healthcare & Pharmaceutical The KPMG Healthcare Meaningful Use Readiness Assessment identifies and summarizes the top 10 Stage One Compliance common challenges.

Pushing the Boundaries of Pharmacovigilance Shared Services and Outsourcing Institute | Jan. 23, 2012 | Healthcare & Pharmaceutical Several highly engaged pharmacovigilance professionals tell KMPG what is "top of mind" in their organizations.

 (1)

Factors to Consider When Reviewing CMS's Draft Federal Upper Limits and Weighted Average Manufacturer Price Files Healthcare & Pharmaceutical Institute | Jan. 18, 2012 | Healthcare & Pharmaceutical This paper focuses on various factors to consider when reviewing CMS' draft Federal Upper Limits and Weighted Average Manufacturer Price Files.

More insights...